A longtime tenant of the University of Houston's Technology Bridge, Indapta Therapeutics has advanced cutting-edge cancer therapies since 2020. In December 2024, the biotechnology company secured $22.5 million in funding to accelerate the clinical development of its lead candidate, IDP-023—an allogeneic g-NK (FcRγ-deficient natural killer) cell therapy naturally engineered to treat cancer and autoimmune diseases. The round was backed by continued support from RA Capital Management, Leaps by Bayer, Vertex Ventures HC, Pontifax, and the Myeloma Investment Fund.
Clinical Progress and Collaborations
IDP-023 is undergoing a Phase 1 trial for relapsed/refractory non-Hodgkin’s lymphoma and multiple myeloma. Preliminary data presented at the Society for Immunotherapy of Cancer meeting indicated a mean maximum reduction of 73% in serum M-protein or light chain levels among responding myeloma patients.
“At Indapta, we are advancing the promise of g-NK cells—an adaptive natural killer cell subset—as a novel approach to treating serious diseases,” said Matthew Collinson-Pautz, Indapta’s Director of Preclinical and Translational Research. “Our lead asset, IDP-023, is an allogeneic g-NK cell therapy designed to be administered in combination with therapeutic monoclonal antibodies.”
Collinson-Pautz noted that recent clinical milestones have further strengthened the company’s confidence in its innovative therapy.
“This year, we are particularly encouraged by the ongoing progress of our clinical trial in patients with relapsed/refractory multiple myeloma. We’ve already shared compelling data at AACR demonstrating the activity of IDP-023 as a monotherapy in advanced r/r multiple myeloma,” he said. “In the months ahead, we look forward to presenting initial results from combination cohorts that pair IDP-023 with monoclonal antibodies—an important milestone in our clinical development roadmap.”
Separately, the FDA cleared an Investigational New Drug (IND) application for a Phase 1 trial of IDP-023 in progressive multiple sclerosis (MS), to be conducted in partnership with Stanford University and UCSF. This approach combines IDP-023 with ocrelizumab, aiming to enhance B-cell depletion and target autoreactive immune cells.
Regulatory Recognition and Support
In February 2024, the FDA granted Fast Track designation to IDP-023 for the treatment of non-Hodgkin’s lymphoma and multiple myeloma, facilitating expedited development and review processes.
Furthermore, Indapta received a $4.5 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) in May 2024 to support the continued clinical development of IDP-023.
About Indapta Therapeutics
Indapta Therapeutics is developing a proprietary platform based on naturally occurring g-NK cells to create potent, scalable, and accessible off-the-shelf therapies for patients with blood cancers, solid tumors, and autoimmune diseases. The company's early development at UH's Technology Bridge underscores the university's role in fostering innovative biotech ventures.
For more information, visit www.indapta.com.